The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Bryan E. Jones(Eli Lilly (United States)), Patricia Brown‐Augsburger(Eli Lilly (United States)), Kizzmekia S. Corbett(National Institutes of Health), Kathryn Westendorf(AbCellera (Canada)), Julian Davies(Eli Lilly (United States)), Thomas P. Cujec(Eli Lilly (United States)), Christopher M. Wiethoff(Eli Lilly (United States)), Jamie L. Blackbourne(Eli Lilly (United States)), Beverly A. Heinz(Eli Lilly (United States)), Denisa Foster(Eli Lilly (United States)), Richard E. Higgs(Eli Lilly (United States)), Deepa Balasubramaniam(Eli Lilly (United States)), Lingshu Wang(National Institutes of Health), Yi Zhang(National Institutes of Health), Eun Sung Yang(National Institutes of Health), Roza Bidshahri(AbCellera (Canada)), Lucas Kraft(AbCellera (Canada)), Yuri Hwang(AbCellera (Canada)), Stefanie Žentelis(AbCellera (Canada)), Kevin R. Jepson(AbCellera (Canada)), Rodrigo Goya(AbCellera (Canada)), Maia A. Smith(AbCellera (Canada)), David W. Collins(AbCellera (Canada)), Samuel J. Hinshaw(AbCellera (Canada)), Sean A. Tycho(AbCellera (Canada)), Davide Pellacani(AbCellera (Canada)), Ping Xiang(AbCellera (Canada)), Krithika Muthuraman(AbCellera (Canada)), Solmaz Sobhanifar(AbCellera (Canada)), Marissa H. Piper(Eli Lilly (United States)), Franz J. Triana(Eli Lilly (United States)), J. Hendle(Eli Lilly (United States)), Anna Pustilnik(Eli Lilly (United States)), Andrew C. Adams(Eli Lilly (United States)), Shawn Berens(Eli Lilly (United States)), Ralph S. Baric(University of North Carolina at Chapel Hill), David R. Martinez(University of North Carolina at Chapel Hill), Robert W. Cross(The University of Texas Medical Branch at Galveston), Thomas W. Geisbert(The University of Texas Medical Branch at Galveston), Viktoriya Borisevich(The University of Texas Medical Branch at Galveston), Olubukola M. Abiona(National Institutes of Health), Hayley M. Belli(New York University), Maren de Vries(New York University), Adil Mohamed(New York University), Meike Dittmann(New York University), Marie I. Samanovic(NYU Langone Health), Mark J. Mulligan(NYU Langone Health), Jory A. Goldsmith(The University of Texas at Austin), Ching‐Lin Hsieh(The University of Texas at Austin), Nicole V. Johnson(The University of Texas at Austin), Daniel Wrapp(The University of Texas at Austin), Jason S. McLellan(The University of Texas at Austin), Bryan C. Barnhart(AbCellera (Canada)), Barney S. Graham(National Institutes of Health), John R. Mascola(National Institutes of Health), Carl L. Hansen(AbCellera (Canada)), Ester Falconer(AbCellera (Canada))
Cited by 496Open Access
Abstract
, consistent with a typical human therapeutic antibody. In a rhesus macaque challenge model, prophylactic doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract in samples collected through study day 6 after viral inoculation. This antibody has entered clinical testing and is being evaluated across a spectrum of COVID-19 indications, including prevention and treatment.
Related Papers
No related papers found
Powered by citation graph analysis